<DOC>
	<DOCNO>NCT01629667</DOCNO>
	<brief_summary>To study safety effectiveness multiple-doses tralokinumab pulmonary function adult mild moderate idiopathic pulmonary fibrosis ( IPF ) . IPF chronic , progressive , irreversible , usually fatal lung disease unknown cause .</brief_summary>
	<brief_title>A Phase 2 , Randomized Dose-ranging Study Evaluate Efficacy Tralokinumab Adults With Idiopathic Pulmonary Fibrosis</brief_title>
	<detailed_description>The primary objective study determine effect multiple dos tralokinumab pulmonary function adult mild moderate IPF</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key 1 ) IPF diagnosis ≤ 5 year prior Visit 1 ( screen ) . Confirmation diagnosis IPF accordance require subject inclusion 2 ) Confirmed diagnosis IPF clinical characteristic , HRCT surgical lung biopsy ( require ) 3 ) Mild moderate IPF include follow screening : 1 . FVC ≥ 50 % predict normal 2 . Partial pressure oxygen arterial blood ( PaO2 ) ≥ 55 mmHg room air 50 mmHg high altitude ( &gt; 1500 meter ) , oxygen saturation pulse oximetry ( SpO2 ) ≥ 90 % room air rest 3 . Hemoglobincorrected diffusion capacity carbon monoxide ( DLCO ) ≥ 30 % predict normal 4 ) Be able walk ≥ 100 meter unassisted Key 1 . A FEV1/FVC ratio le 0.70 time screening ( postbronchodilator ) 2 . The extent emphysema HRCT great extent fibrosis . 3 . Currently list lung transplantation 4 . Use following medication : 1 . Immunosuppressive medication ( eg , methotrexate , cyclosporine , azathioprine , intramuscular longacting depot corticosteroid ) within 3 month prior Visit 1 ( screen ) . Oral prednisone ≤ 15 mg/day ( equivalent oral corticosteroid ) allow chronic use subject stable dose least 30 day prior Visit 1 ( screen ) 2 . Pirfenidone within 4 week prior Visit 1 ( screen ) 3 . Nacetylcysteine within 4 week prior Visit 1 ( screen ) 4 . Live attenuate vaccine within 4 week prior Visit 1 ( screen )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>